Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination

• Published in: Vaccines (Basel) Vol. 9; no. 5; p. 435
• Main Authors: Watad, Abdulla, De Marco, Gabriele, Mahajna, Hussein, Druyan, Amit, Eltity, Mailam, Hijazi, Nizar, Haddad, Amir, Elias, Muna, Zisman, Devy, Naffaa, Mohammad E., Brodavka, Michal, Cohen, Yael, Abu-Much, Arsalan, Abu Elhija, Muhanad, Bridgewood, Charlie, Langevitz, Pnina, McLorinan, Joanna, Bragazzi, Nicola Luigi, Marzo-Ortega, Helena, Lidar, Merav, Calabrese, Cassandra, Calabrese, Leonard, Vital, Edward, Shoenfeld, Yehuda, Amital, Howard, McGonagle, Dennis
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 29.04.2021; MDPI
• Subjects: adenoviral vector-based vaccine; Adjuvanticity; Antigens; Arthritis; Coronaviruses; Corticosteroids; COVID-19; COVID-19 vaccines; Demyelination; Disease; DNA vaccines; Evaluation; FDA approval; Flares; Immune system; immune-mediated diseases; Immunization; Infections; Infectious diseases; Inflammation; mRNA; mRNA-based vaccine; Myasthenia gravis; Nervous system diseases; Neuromuscular junctions; Neuropathy; Pandemics; Pericarditis; Phenotypes; Public health; Rheumatic diseases; Sarcoidosis; Severe acute respiratory syndrome coronavirus 2; Side effects; Surveillance; TLR9 protein; Toll-like receptors; vaccine safety; Vaccines; United Kingdom > UK; United States > US; Israel; COVID-19; vaccine safety; mRNA-based vaccine; immune-mediated diseases; adenoviral vector-based vaccine

Background: Infectious diseases and vaccines can occasionally cause new-onset or flare of immune-mediated diseases (IMDs). The adjuvanticity of the available SARS-CoV-2 vaccines is based on either TLR-7/8 or TLR-9 agonism, which is distinct from previous vaccines and is a common pathogenic mechanism...